PE 22-28

TREK-1 Potassium Channel Blockade#

PE 22-28 is a shortened, stabilized 7-amino-acid analog (GVSWGLR) of spadin, a sortilin-derived propeptide. Its core mechanism is selective inhibition of the TREK-1 (KCNK2) two-pore-domain potassium channel — a background K⁺ "leak" channel that sets resting membrane potential in serotonergic neurons of the dorsal raphe, hippocampus, and prefrontal cortex. Blocking TREK-1 depolarizes these neurons, enhances firing, and increases 5-HT release without touching SERT or monoamine reuptake.

The potency gain over spadin is the key engineering win: where spadin sits at ~50 nM on hTREK-1, PE 22-28 operates in the sub-nanomolar range.

"PE 22-28 emerged as a highly potent and stable analog with an IC50 of 0.12 nM on hTREK-1 compared to spadin (50 nM) and a prolonged in vivo antidepressant activity lasting over 24 h." — Djillani A. et al., Frontiers in Pharmacology, 2017

This ~400-fold potency jump, combined with in-vivo stability, is why PE 22-28 displaced spadin as the lead compound in the TREK-1 antidepressant program.

Serotonergic Tone Without SSRI Pharmacology#

TREK-1 is functionally coupled to 5-HT1A autoreceptor signaling in raphe neurons. Removing TREK-1 tone disinhibits serotonergic firing and produces an antidepressant phenotype that is mechanistically upstream of classical reuptake inhibition — which matters clinically for SSRI non-responders and for subjects who cannot tolerate SSRI side-effect profiles (sexual dysfunction, emotional blunting, weight gain).

"Behavioral characterization of TREK-1 knockout mice revealed a phenotype highly resistant to depression, linking the channel's activity to mood regulation and monoaminergic transmission." — Heurteaux C. et al., Nature Neuroscience, 2006

For the physique-focused reader, this is the practical payoff: mood support during aggressive cuts, harsh PCT windows, or post-trenbolone mood troughs — without the libido crash and anorgasmia that make SSRIs a non-starter for anyone running AAS.

BDNF Upregulation and Hippocampal Neurogenesis#

Chronic TREK-1 blockade drives downstream plasticity machinery: BDNF, PSD-95, increased dendritic spine density, and measurable hippocampal neurogenesis (BrdU⁺ cells). This is the same final common pathway SSRIs eventually engage — but PE 22-28 arrives there in days rather than weeks.

"Spadin and its shortened analog PE 22-28 act as fast antidepressants by inhibiting TREK-1 and promoting increased neurogenesis and BDNF pathway activation within just four days." — Djillani A. et al., Pharmacology & Therapeutics, 2019

The ~4-day onset is the single most distinctive feature of this class and the reason it shows up in post-cycle mood protocols: the window where clomid/enclomiphene drag mood hardest is the window where PE 22-28 is already working.

HPA-Axis Dampening#

TREK-1 knockout and spadin-treated animals show blunted corticosterone elevation under acute stress. The translational read is reduced HPA reactivity — relevant for users stacking it into sleep or recovery protocols, and for anyone whose mood crash is being driven by chronic cortisol load (heavy deficit + high training volume + sleep debt). This is also why evening dosing works for some subjects chasing sleep depth, and why morning dosing is the default for everyone else.

Absence of Class-Typical TREK-1 Side Effects#

TREK-1 is also expressed in cardiac tissue and in circuits relevant to seizure threshold, which raised reasonable early concern about arrhythmogenic or proconvulsant signals. Preclinical work has not borne that out.

"Spadin does not induce cardiac or convulsive adverse effects despite TREK-1 expression in heart and brain, supporting a benign safety profile shared with its analogs." — Moha ou Maati H. et al., Neuropharmacology, 2012

The mechanism-based cautions remain — active seizure disorder, arrhythmia history, and concurrent SSRI/MAOI/triptan stacking are still the hard lines — but the preclinical safety envelope is why the research community has been willing to explore PE 22-28 at the doses documented in protocols rather than treating it as experimental-only chemistry.

Common (most users)#

Most subjects tolerate PE 22-28 well across the 125–400mcg range. Reported effects are mild, dose-dependent, and resolve with simple protocol adjustments.

• Transient restlessness or "wired" feeling — most common complaint, typically emerging in the first 3–5 days as serotonergic tone rises. Dropping to 125–200mcg for the first week and titrating up resolves it. This window also lines up with onset of behavioral effect, so pushing through a few days is reasonable before cutting the dose.
• Sleep disruption — almost exclusively tied to evening administration. The fix is mechanical: shift dosing to the morning. Stimulation-sensitive subjects benefit from pre-9am dosing.
• Mild appetite reduction — transient, usually confined to the first week. No meaningful effect on body composition; worth noting for subjects running the compound during a cut who are already managing hunger.
• Mild headache — occasional, early-dosing. Hydration and a 24–48h dose hold or reduction clear it.
• Injection-site redness or minor welts — standard for any subcutaneous peptide. Site rotation (abdomen ↔ flank ↔ thigh), 29–31g insulin pins, and room-temperature solution minimize incidence.

Uncommon (dose-dependent or individual)#

These tend to appear above ~400mcg daily or in susceptible subjects, and are the signal to back off rather than push through.

• Anxiety or jitteriness resembling overstimulation — the dominant complaint at 500–600mcg in stimulation-sensitive subjects. Drop to 250–300mcg; the neurogenic effects are already saturating in that range based on the preclinical data.
• Emotional blunting or "flat" affect — paradoxical but reported in a minority of longer (>4 week) protocols. The fix is cycling off; the published pharmacology supports discrete blocks, not indefinite dosing.
• Mild tachycardia or palpitations — uncommon but plausible given TREK-1 expression in cardiac tissue. Resting HR and BP should be tracked at baseline and weekly; a sustained >10bpm rise or new ectopy is a reason to stop.
• Nasal irritation (intranasal route) — burning, dryness, or post-nasal drip. Splitting the dose between nostrils and rotating to subcutaneous for a week generally resolves it.
• Hypomanic tilt in bipolar-spectrum subjects — any rapid-onset antidepressant mechanism can destabilize bipolar-II presentations. Elevated mood, reduced sleep need, and pressured speech in the first two weeks warrant discontinuation.

Rare but serious#

Low-incidence in the published literature, but mechanism-plausible and worth recognizing early.

• Lowered seizure threshold — TREK-1 normally functions as a neuronal brake; pharmacologic blockade theoretically raises excitability. No seizures surfaced in the preclinical work, but any aura, myoclonic jerk, or frank seizure activity is an immediate stop.
• Serotonin syndrome (in combination protocols) — hyperthermia, clonus, diaphoresis, agitation, tremor. The risk is not from PE 22-28 alone but from stacking it on top of SSRIs, SNRIs, MAOIs, tramadol, MDMA, or triptans. Symptoms escalate fast; discontinue all serotonergic agents and seek care.
• Cardiac arrhythmia — no signal in the available data, but chest pain, syncope, or new palpitations in any subject with pre-existing cardiac history warrant immediate cessation and evaluation.
• Peptide hypersensitivity reaction — urticaria, angioedema, or bronchospasm within minutes of dosing. Rare with 7-residue peptides but documented across the class. Stop and manage as standard anaphylaxis risk.

"Spadin does not induce cardiac or convulsive adverse effects despite TREK-1 expression in heart and brain, supporting a benign safety profile shared with its analogs." — Moha ou Maati et al., Neuropharmacology (2012)

Hard contraindications#

These are the lines that do not get crossed.

• Active seizure disorder or history of epilepsy. TREK-1 blockade is mechanistically pro-excitatory. Exclude.
• Concurrent SSRIs, SNRIs, MAOIs, tramadol, triptans, MDMA, or linezolid. Serotonin-syndrome risk is mechanism-driven. Serotonergic agents must be tapered and washed out before initiation — SSRIs require 1–2 weeks, fluoxetine 5+ weeks, MAOIs 14 days.
• Cardiac arrhythmia history, long-QT syndrome, or structural heart disease. Human cardiac safety is uncharacterized; the prudent position is exclusion.
• Pregnancy and lactation. No data. Excluded from both states.
• Known peptide hypersensitivity. Prior anaphylactoid reaction to any research peptide is a hard exclusion.
• Bipolar I disorder with mania history. Any rapid-onset antidepressant mechanism carries manic-switch risk.

Gender considerations and cycle logistics#

PE 22-28 is non-hormonal, non-suppressive, and bodyweight-independent — the same dose ranges apply across the subject pool regardless of sex, and there is no virilization, menstrual, or HPTA concern. No PCT is required and none is useful; the compound does not interact with AAS pharmacology and can be run through PCT to cover the mood trough without compromising recovery protocols.

Female subjects are excluded during pregnancy and lactation due to absent reproductive-safety data. Subjects running PE 22-28 alongside AAS, GH, or other hormonal protocols continue their standard CBC / CMP / lipid / hormonal panel cadence — PE 22-28 itself does not require additional bloodwork, though baseline and 4-week mood tracking (PHQ-9 or equivalent) is the most useful objective endpoint for confirming response.